Glioblastoma Multiforme Clinical Trials

95 recruitingLast updated: June 17, 2026

There are 95 actively recruiting glioblastoma multiforme clinical trials across 23 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Glioblastoma Multiforme Trials at a Glance

95 actively recruiting trials for glioblastoma multiforme are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 1 with 42 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running glioblastoma multiforme studies include Northwell Health, Jasper Gerritsen, and Institute of Cancer Research, United Kingdom.

Browse glioblastoma multiforme trials by phase

Treatments under study

About Glioblastoma Multiforme Clinical Trials

Looking for clinical trials for Glioblastoma Multiforme? There are currently 63 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma Multiforme trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma Multiforme clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 95 trials

Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Glioblastoma Multiforme
National Cancer Institute (NCI)200 enrolled1 locationNCT00083512
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 1

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

GlioblastomaGliomaGlioblastoma Multiforme of Brain
Tetragon Biosciences Ltd30 enrolled3 locationsNCT07464925
Recruiting
Phase 1Phase 2

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

GliomaGlioblastoma Multiforme
Aveta Biomics, Inc.30 enrolled2 locationsNCT06011109
Recruiting

Loupe-Based Intraoperative Fluorescence Imaging

Glioblastoma MultiformeAnaplastic Astrocytoma
Guoqiang Yu30 enrolled1 locationNCT04780009
Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Not Applicable

Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial

Glioblastoma Multiforme
BioTex, Inc.30 enrolled6 locationsNCT06533163
Recruiting
Phase 1Phase 2

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Glioblastoma MultiformeAnaplastic Astrocytoma
Northwell Health54 enrolled1 locationNCT01269853
Recruiting
Phase 3

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Brain CancerGlioblastomaGBM+4 more
Northwell Health432 enrolled1 locationNCT05271240
Recruiting
Phase 1Phase 2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

CancerBrain TumorBrain Cancer+6 more
Northwell Health67 enrolled1 locationNCT03213002
Recruiting
Not Applicable

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

Brain CancerGlioblastomaGBM+4 more
Northwell Health32 enrolled1 locationNCT05954858
Recruiting
Not Applicable

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

Brain CancerGlioblastomaGBM+5 more
Northwell Health10 enrolled1 locationNCT05979064
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

GliomasGlioma Glioblastoma MultiformeGliomas Harboring IDH1 and/or IDH2 Mutations+3 more
Xiangya Hospital of Central South University500 enrolled1 locationNCT07608003
Recruiting
Phase 1

IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma

GlioblastomaGlioblastoma Multiforme
University of Florida39 enrolled1 locationNCT05353530
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaNon-small Cell Lung Cancer+8 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting

MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy

Glioblastoma Multiforme
University of Sydney20 enrolled2 locationsNCT05500612
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388